{"id":3110,"date":"2025-11-07T11:53:42","date_gmt":"2025-11-07T10:53:42","guid":{"rendered":"https:\/\/www.monitorcm.se\/?p=3110"},"modified":"2025-11-07T11:53:42","modified_gmt":"2025-11-07T10:53:42","slug":"handla-aktier-i-a3p-biomedical-ab","status":"publish","type":"post","link":"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/","title":{"rendered":"Trade shares in A3P Biomedical AB"},"content":{"rendered":"

A3P Biomedical is a Swedish medical technology company focused on prostate cancer diagnostics. The company's main product, <\/span>Stockholm3 is a blood-based test that combines protein markers, genetic markers and clinical data to identify the risk of aggressive prostate cancer. The technology enables early detection of severe cases, even in men with low or normal PSA levels. The company is headquartered in Stockholm and collaborates with research institutes and healthcare providers across Europe.<\/span><\/p>\n

Stockholm3 an innovation in prostate cancer diagnostics<\/b><\/h2>\n

Traditional PSA tests have long been used as a first-line screening method, but have limited reliability. A3P Biomedical has developed Stockholm3 as a more accurate tool for healthcare. The test uses an algorithm that weighs together multiple biomarkers to assess the likelihood of clinically significant cancer.<\/span><\/p>\n

Results from large studies involving over 90,000 participants show that Stockholm3 can detect up to 89 % more cases of aggressive prostate cancer, while reducing the number of unnecessary examinations by up to 52 %. The studies have been published in scientific journals such as <\/span>The Lancet Oncology<\/span><\/i>, <\/span>Journal of Clinical Oncology<\/span><\/i> and <\/span>European Urology<\/span><\/i>. The research points to both medical and health economic benefits of the test.<\/span><\/p>\n

Invest in A3P Biomedical<\/b><\/h2>\n

A3P Biomedical is an unlisted company, which means that the share is not traded on any stock exchange. Through Monitor Capital Markets, which is a licensed broker under the supervision of the Swedish Financial Supervisory Authority, investors can be given the opportunity to trade shares in certain unlisted companies. Trading is done by matching buyers and sellers and is not a public offering.<\/span><\/p>\n

Investing in unlisted companies involves high risk and limited liquidity. It may be difficult to sell the shares and there is no guarantee of future returns. The information on this page does not constitute investment advice but is intended as general information. Anyone considering an investment should carefully read the company's public documents and, if necessary, consult an independent financial adviser.<\/span><\/p>\n

Are you interested in investing?<\/strong><\/p>\n

Contact us<\/a> for more information on how to trade and how you can become a shareholder.<\/span><\/p>\n

Other unlisted companies investors follow<\/b><\/h3>\n

byWiT | Exeger | Xshore | Altris<\/span><\/p>","protected":false},"excerpt":{"rendered":"

A3P Biomedical \u00e4r ett svenskt medicintekniskt bolag som fokuserar p\u00e5 diagnostik av prostatacancer. Bolagets huvudprodukt, Stockholm3 \u00e4r ett blodbaserat test som kombinerar proteinmark\u00f6rer, genetiska mark\u00f6rer och kliniska data f\u00f6r att identifiera risken f\u00f6r aggressiv prostatacancer. Tekniken g\u00f6r det m\u00f6jligt att uppt\u00e4cka allvarliga fall i tid, \u00e4ven hos m\u00e4n med l\u00e5ga eller normala PSA-v\u00e4rden. Bolaget har […]\n","protected":false},"author":2,"featured_media":3111,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[60],"tags":[],"acf":[],"yoast_head":"\nHandla aktier i A3P Biomedical AB – Monitor Capital Markets<\/title>\n<meta name=\"description\" content=\"A3P Biomedical utvecklar Stockholm3, ett innovativt blodtest som revolutionerar diagnostiken av prostatacancer. Ett svenskt tillv\u00e4xtbolag med potential.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Handla aktier i A3P Biomedical AB – Monitor Capital Markets\" \/>\n<meta property=\"og:description\" content=\"A3P Biomedical utvecklar Stockholm3, ett innovativt blodtest som revolutionerar diagnostiken av prostatacancer. Ett svenskt tillv\u00e4xtbolag med potential.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/\" \/>\n<meta property=\"og:site_name\" content=\"Monitor Capital Markets\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T10:53:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pontus N\u00e4ss\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pontus N\u00e4ss\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/\"},\"author\":{\"name\":\"Pontus N\u00e4ss\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\"},\"headline\":\"Handla aktier i A3P Biomedical AB\",\"datePublished\":\"2025-11-07T10:53:42+00:00\",\"dateModified\":\"2025-11-07T10:53:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/\"},\"wordCount\":389,\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg\",\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/\",\"url\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/\",\"name\":\"Handla aktier i A3P Biomedical AB – Monitor Capital Markets\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg\",\"datePublished\":\"2025-11-07T10:53:42+00:00\",\"dateModified\":\"2025-11-07T10:53:42+00:00\",\"description\":\"A3P Biomedical utvecklar Stockholm3, ett innovativt blodtest som revolutionerar diagnostiken av prostatacancer. Ett svenskt tillv\u00e4xtbolag med potential.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg\",\"width\":1000,\"height\":667,\"caption\":\"k\u00f6p aktier a3p biomedical\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\/\/www.monitorcm.se\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Handla aktier i A3P Biomedical AB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.monitorcm.se\/#website\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"name\":\"Monitor Capital Markets\",\"description\":\"Finansiellt M\u00e4kleri med fokus p\u00e5 onoterade bolag och aktier\",\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.monitorcm.se\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.monitorcm.se\/#organization\",\"name\":\"Monitor Capital Markets\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"width\":720,\"height\":120,\"caption\":\"Monitor Capital Markets\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\",\"name\":\"Pontus N\u00e4ss\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trade shares in A3P Biomedical AB - Monitor Capital Markets","description":"A3P Biomedical develops Stockholm3, an innovative blood test that revolutionizes the diagnosis of prostate cancer. A Swedish growth company with potential.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/","og_locale":"en_US","og_type":"article","og_title":"Handla aktier i A3P Biomedical AB – Monitor Capital Markets","og_description":"A3P Biomedical utvecklar Stockholm3, ett innovativt blodtest som revolutionerar diagnostiken av prostatacancer. Ett svenskt tillv\u00e4xtbolag med potential.","og_url":"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-a3p-biomedical-ab\/","og_site_name":"Monitor Capital Markets","article_published_time":"2025-11-07T10:53:42+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg","type":"image\/jpeg"}],"author":"Pontus N\u00e4ss","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pontus N\u00e4ss","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#article","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/"},"author":{"name":"Pontus N\u00e4ss","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355"},"headline":"Handla aktier i A3P Biomedical AB","datePublished":"2025-11-07T10:53:42+00:00","dateModified":"2025-11-07T10:53:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/"},"wordCount":389,"publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"image":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg","articleSection":["Nyheter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/","url":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/","name":"Trade shares in A3P Biomedical AB - Monitor Capital Markets","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage"},"image":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg","datePublished":"2025-11-07T10:53:42+00:00","dateModified":"2025-11-07T10:53:42+00:00","description":"A3P Biomedical develops Stockholm3, an innovative blood test that revolutionizes the diagnosis of prostate cancer. A Swedish growth company with potential.","breadcrumb":{"@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#primaryimage","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/a3p-biomedical-1.jpg","width":1000,"height":667,"caption":"k\u00f6p aktier a3p biomedical"},{"@type":"BreadcrumbList","@id":"https:\/\/www.monitorcm.se\/handla-aktier-i-a3p-biomedical-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.monitorcm.se\/"},{"@type":"ListItem","position":2,"name":"Handla aktier i A3P Biomedical AB"}]},{"@type":"WebSite","@id":"https:\/\/www.monitorcm.se\/#website","url":"https:\/\/www.monitorcm.se\/","name":"Monitor Capital Markets","description":"Financial Brokerage with focus on unlisted companies and shares","publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.monitorcm.se\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.monitorcm.se\/#organization","name":"Monitor Capital Markets","url":"https:\/\/www.monitorcm.se\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","width":720,"height":120,"caption":"Monitor Capital Markets"},"image":{"@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/"]},{"@type":"Person","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355","name":"Pontus N\u00e4ss"}]}},"_links":{"self":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3110"}],"collection":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/comments?post=3110"}],"version-history":[{"count":2,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3110\/revisions"}],"predecessor-version":[{"id":3113,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3110\/revisions\/3113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media\/3111"}],"wp:attachment":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media?parent=3110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/categories?post=3110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/tags?post=3110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}